EMOVI RECOGNIZED AS ONE OF THE TOP MEDICAL TECHNOLOGY STARTUPS IN 2018

Emovi has been selected from over 700 applicants to participate in the MedTech Innovator 2018 Showcase Program to be recognized as one of the top startups in the MedTech industry for 2018. MedTech Innovator is recognized as one of eight accelerators in the nation by the U.S. Department of Health and Human Services to drive innovation in medical technologies that solve challenging problems spanning modern health security problems and daily medical care.   “Our team is honored by the opportunity to showcase and promote our advanced technology, KneeKG, with the ultimate goal of delivering better knee care at a lower cost,” said Michelle Laflamme, CEO, Emovi.

KneeKG is the first 3D High-Tech Dynamic Knee Assessment tool that enables a Knee Kinesiography test in-clinic and serves as the ultimate and best quality measurement device to (i) help quickly diagnose pathologic patterns in relation to knee pain (ii) develop a focused treatment strategy to restore optimal knee function, and (iii) document outcomes/clinical benefits of the precribed treatment regimen.

More about MedTech Innovator announcement

About Emovi
Emovi (Emovi.ca), headquartered in Montreal, Quebec, Canada, is a company offering medical solutions for knee joints. In partnership with the Quebec university research community, including the CRCHUM and École de technologie supérieure (ÉTS), Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive license to commercialize the KneeKG and has commenced commercialization in Canada, the United States, Europe, Australia and Asia. Emovi hopes to broaden access to this technology and improve the quality of life for people struggling with diseases such as knee arthritis, ligament or meniscus tears, patellofemoral syndrome, tendonitis and biomechanical deficiencies resulting in pain and disability.